|
|
Volumn 31, Issue 1, 2013, Pages 1-
|
|
Failure to launch
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
17 METHYLNALTREXONE;
4 AMINOPYRIDINE;
AFLIBERCEPT;
ALVIMOPAN;
ANASCORP;
ANTISERUM;
AXITINIB;
BELIMUMAB;
CLOSTRIDIOPEPTIDASE A;
DRONEDARONE;
ECALLANTIDE;
FERUMOXYTOL;
GABAPENTIN ENACARBIL;
LINAGLIPTIN;
OFATUMUMAB;
PEGLOTICASE;
PRALATREXATE;
RECOMBINANT ANTITHROMBIN III;
RECOMBINANT THROMBIN;
SIPULEUCEL T;
SITAGLIPTIN;
SORAFENIB;
THROMBIN;
TICAGRELOR;
UNCLASSIFIED DRUG;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
EDITORIAL;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
REIMBURSEMENT;
RISK ASSESSMENT;
BIOTECHNOLOGY;
DRUG INDUSTRY;
INCOME;
REIMBURSEMENT MECHANISMS;
|
|
EID: 84872186754
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.2482 Document Type: Editorial |
|
Times cited : (4)
|
|
References (0)
|